Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by Regenera Pharma Ltd
Sponsor:
Collaborator:
Kendle Toronto, Inc, a wholly-owned subsidiary of INC Research LLC
Information provided by (Responsible Party):
Regenera Pharma Ltd
ClinicalTrials.gov Identifier:
NCT01513967
First received: January 17, 2012
Last updated: December 6, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2014
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)